Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow

Int J Hematol. 2006 Jan;83(1):74-9. doi: 10.1532/IJH97.05124.

Abstract

Reduced-intensity (RI) conditioning followed by cord blood transplantation (CBT) is a new treatment modality, but failure to engraft is a major concern. We describe 12 patients with advanced hematologic malignancies who underwent RI conditioning and CBT with a conditioning regimen consisting of 200 mg/m(2) fludarabine (Flu), 50 mg/kg cyclophosphamide (CY), and 3 Gy total body irradiation (TBI). Cyclosporin A and/or methotrexate were used for graft-versus-host disease prophylaxis. Cord blood grafts were not mismatched for more than 2 serologically defined HLA alleles but were later found by high-resolution DNA typing to be mismatched for 2 to 4 alleles in most cases. Short tandem repeat analysis of bone marrow cells at day 14 showed complete donor chimerism in 6 of the patients and mixed chimerism in 5, indicating rapid engraftment in the bone marrow, whereas the remaining patient experienced graft rejection. Neutrophil recovery was achieved at a median of day 17 (range, days 11-24) in 10 of the 11 patients with marrow chimerism at day 14. Of these 10 patients, however, transplantation-related mortality within 100 days occurred in 4 patients who showed failed platelet recovery and a lack of durable engraftment. Overall survival and disease-free survival rates were 41.7% and 33.3%, respectively. These results show that CB mismatched at 2 to 4 HLA alleles and transplanted with the Flu/CY/3 Gy TBI regimen is able to engraft in the bone marrow as early as day 14.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bone Marrow
  • Cord Blood Stem Cell Transplantation* / methods
  • Cord Blood Stem Cell Transplantation* / mortality
  • Cyclophosphamide / administration & dosage
  • Cyclosporine / administration & dosage
  • Disease-Free Survival
  • Female
  • Graft Survival* / drug effects
  • Graft Survival* / radiation effects
  • Graft vs Host Disease / prevention & control
  • Hematologic Neoplasms / mortality
  • Hematologic Neoplasms / therapy*
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Myeloablative Agonists / administration & dosage
  • Transplantation Chimera
  • Transplantation Conditioning* / methods
  • Transplantation Conditioning* / mortality
  • Treatment Outcome
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives
  • Whole-Body Irradiation / methods
  • Whole-Body Irradiation / mortality

Substances

  • Immunosuppressive Agents
  • Myeloablative Agonists
  • Cyclosporine
  • Cyclophosphamide
  • Vidarabine
  • fludarabine
  • Methotrexate